• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Strobeck Matthew

    5/22/25 4:16:43 PM ET
    $BDSX
    Medical Specialities
    Health Care
    Get the next $BDSX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Strobeck Matthew

    (Last) (First) (Middle)
    919 WEST DILLON RD

    (Street)
    LOUISVILLE CO 80027

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIODESIX INC [ BDSX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units (1) 05/20/2025 A 80,525 (2) (2) Common Stock 80,525 $0 80,525(3) D
    Stock Options (Right to Buy) $0.2708 05/20/2025 A 42,010 (4) 05/19/2035 Common Stock 42,010 $0 42,010 D
    Explanation of Responses:
    1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
    2. These RSUs will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
    3. Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
    4. This option will vest in three substantially equal installments on June 30, September 30 and December 31, 2025, generally subject to the Reporting Person's continued service with the Issuer.
    /s/ Robin H. Cowie as Attorney-in-Fact for Matthew Strobeck 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BDSX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDSX

    DatePrice TargetRatingAnalyst
    5/14/2025Outperform → Mkt Perform
    William Blair
    9/16/2024Sector Outperform
    Scotiabank
    7/26/2024$3.00Buy
    Craig Hallum
    5/13/2024$2.80Buy
    TD Cowen
    5/3/2024$3.00Buy
    Lake Street
    11/17/2021$21.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BDSX
    SEC Filings

    View All

    SEC Form 10-Q filed by Biodesix Inc.

    10-Q - BIODESIX INC (0001439725) (Filer)

    8/7/25 4:11:36 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BIODESIX INC (0001439725) (Filer)

    8/7/25 4:05:32 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Biodesix Inc.

    S-8 - BIODESIX INC (0001439725) (Filer)

    5/30/25 4:10:49 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

    LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher's collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix Development Services offerings, including customizable options that enable the world's leading life sciences companies, biopharmaceutical, and medical research institutions with scientific, technological, and operational capabilities. As Thermo Fisher announced in July 2025, Biodesix was an instrumental partner in the vali

    8/19/25 9:47:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Second Quarter 2025 Results and Highlights

    Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial

    8/7/25 4:06:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

    BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Canaccord Genuity 45th Annual Growth Conference Fireside Chat Date: Tuesday, August 12, 2025Fireside Chat Time: 4:30 PM ETLocation: Boston, MA The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company's website at biodesix.com. About Biodesix Biodesix is

    8/5/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO, Sec'y & Treasurer Cowie Robin Harper converted options into 3,157 shares and sold $411 worth of shares (988 units at $0.42), increasing direct ownership by 0.87% to 250,794 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    8/14/25 5:25:14 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Development Officer Pestano Gary Anthony converted options into 1,379 shares and sold $184 worth of shares (442 units at $0.42), increasing direct ownership by 0.60% to 157,878 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    8/14/25 5:24:35 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Chief Commercial Officer O'Kane Kieran converted options into 1,489 shares and sold $198 worth of shares (476 units at $0.42), increasing direct ownership by 0.73% to 140,065 units (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    8/14/25 5:24:51 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Financials

    Live finance-specific insights

    View All

    Biodesix Announces Second Quarter 2025 Results and Highlights

    Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. "We had strong second quarter performance with 12% revenue growth and 80% gross margins," said Scott Hutton, Chief Executive Officer. "Last quarter, we expanded our commercial

    8/7/25 4:06:26 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

    LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after t

    7/24/25 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces First Quarter 2025 Results and Highlights

    Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. "Our quarter was highlighted by continued progress toward our three key goals for 2025 – growing top line revenue, improving operational efficiencies and leverage, and advancing our pipeline," said Sc

    5/13/25 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Leadership Updates

    Live Leadership Updates

    View All

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo

    12/16/22 4:01:00 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Biodesix Announces Appointment of Successful Innovator and Scientific Professional Jon Faiz Kayyem, PhD to Board of Directors

    Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a

    12/8/21 6:00:00 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodesix Inc.

    SC 13G/A - BIODESIX INC (0001439725) (Subject)

    11/13/24 7:30:22 AM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Biodesix Inc.

    SC 13G - BIODESIX INC (0001439725) (Subject)

    6/24/24 12:16:38 PM ET
    $BDSX
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Biodesix Inc. (Amendment)

    SC 13D/A - BIODESIX INC (0001439725) (Subject)

    5/23/24 7:10:37 PM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biodesix downgraded by William Blair

    William Blair downgraded Biodesix from Outperform to Mkt Perform

    5/14/25 8:54:25 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Scotiabank initiated coverage on Biodesix

    Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform

    9/16/24 8:45:16 AM ET
    $BDSX
    Medical Specialities
    Health Care

    Craig Hallum initiated coverage on Biodesix with a new price target

    Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00

    7/26/24 7:48:11 AM ET
    $BDSX
    Medical Specialities
    Health Care

    $BDSX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schuler Jack W bought $1,316,624 worth of shares (4,723,239 units at $0.28) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    5/20/25 4:11:31 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Schuler Jack W bought $122,840 worth of shares (100,000 units at $1.23) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/22/24 12:30:34 PM ET
    $BDSX
    Medical Specialities
    Health Care

    Director Kennedy Lawrence T. Jr bought $40,562 worth of shares (35,000 units at $1.16) (SEC Form 4)

    4 - BIODESIX INC (0001439725) (Issuer)

    11/22/24 12:30:13 PM ET
    $BDSX
    Medical Specialities
    Health Care